Recruiting Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells NCT06347068 Conditions Breast Cancer, Breast Diseases, Breast Neoplasms, +12 more Locations University of North Carolina — Chapel Hill, North Carolina, United States View Trial Details
Recruiting Autologous CAR-T Cells Targeting B7-H3 in PDAC NCT06158139 Conditions Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, +12 more Locations University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina, United States View Trial Details
Recruiting Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET NCT05889312 Conditions Acute-Phase Reaction, Cancer, Diagnosis, +7 more Locations Guy's and St Thomas' NHS Foundation Trust — London, United Kingdom View Trial Details
Not Yet Recruiting A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma NCT07535840 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more Locations Not specified View Trial Details
Active, Not Recruiting 9-ING-41 in Patients With Advanced Cancers NCT03678883 Conditions Acute T Cell Leukemia Lymphoma, Bone Cancer, Bone Diseases, +90 more Locations Mayo Clinic — Phoenix, Arizona, United States Arizona Oncology Associates — Tucson, Arizona, United States The University of Arizona Cancer Center — Tucson, Arizona, United States University of California Irvine Health — Orange, California, United States View all 66 locations View more locations Show fewer locations Loading locations... View Trial Details
